Journey Medical Corporation DERM Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| Revenue by Product | |||
| Accutane | $12.88M-33.6% | $19.41M-3.8% | |
| Emrosi | $14.75M— | —— | |
| Foam Franchise Products Amzeeq Zilxi | $5.86M— | —— | |
| Other Legacy | $2.74M-30.9% | $3.96M-33.1% | |
| Qbrexza | $25.02M-0.4% | $25.12M-1.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Journey Medical Corporation break its business down?
- Journey Medical Corporation (DERM) reports revenue by product across 5 parts — Accutane, Emrosi, Foam Franchise Products Amzeeq Zilxi, Other Legacy and Qbrexza. Each is extracted from the segment footnotes and tracked over time.
- Where does Journey Medical Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Journey Medical Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
